Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Passage Bio Inc

Healthcare US PASG

5.88USD
-0.24(3.92%)

Last update at 2026-06-24T20:00:00Z

Day Range

5.786.30
LowHigh

52 Week Range

0.571.79
LowHigh

Fundamentals

  • Previous Close 6.12
  • Market Cap73.35M
  • Volume50502
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-92.91700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -136.12500M -185.38600M -112.23200M -45.63400M -12.77000M
Minority interest - - - - -
Net income -136.85600M -191.50000M -111.76200M -54.57900M -12.77000M
Selling general administrative 49.34M 60.06M 30.11M 6.95M 0.93M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 3.68M 1.54M 0.80M 0.13M 0.00000M
Ebit -138.39400M -185.72900M -112.90200M -37.18900M -8.11600M
Ebitda -132.39400M -169.72900M -110.90200M -26.91400M -7.42000M
Depreciation and amortization 6.00M 16.00M 2.00M 10.28M 0.70M
Non operating income net other 1.72M -0.05800M 0.67M - -
Operating income -138.39400M -185.72900M -112.90200M -37.18900M -13.46600M
Other operating expenses 135.39M 177.73M 111.90M 36.69M 10.10M
Interest expense 2.27M 0.34M 0.67M 8.45M 0.70M
Tax provision - - - - -
Interest income 2.27M 0.34M 0.67M 0.70M 0.00000M
Net interest income 2.27M 0.34M 0.67M 0.70M 0.00000M
Extraordinary items - - - - -
Non recurring 3.00M 8.00M 1.00M - -
Other items - - - - -
Income tax expense 0.73M 6.11M -0.47000M 8.95M -0.69600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 135.39M 177.73M 111.90M 36.69M 10.10M
Cost of revenue - - - - -
Total other income expense net 2.27M 0.34M 0.67M -8.44500M -2.67500M
Discontinued operations - - - - -
Net income from continuing ops -136.67800M -185.78700M -112.23200M -45.63400M -12.77000M
Net income applicable to common shares -136.12500M -185.38600M -112.23200M -45.63400M -12.77000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 150.54M 243.55M 355.08M 328.01M 178.61M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.67M 0.93M 1.73M 12.37M 6.90M
Total liab 39.26M 42.18M 36.42M 23.29M 4.26M
Total stockholder equity 111.28M 201.37M 318.66M 304.71M 174.35M
Deferred long term liab - - - 0.20M 1.70M
Other current liab 11.67M 11.01M 20.05M 15.91M 3.05M
Common stock 0.00500M 0.00500M 0.00500M 0.00400M 0.00300M
Capital stock 0.00500M 0.00500M 0.00500M 0.00400M 0.00300M
Retained earnings -594.46800M -492.40600M -356.28100M -170.89500M -58.66300M
Other liab - - 6.92M 2.12M 0.58M
Good will - - - - -
Other assets 0.00000M 4.27M 6.20M 2.79M 11.75M
Cash 21.71M 34.60M 128.97M 135.00M 158.87M
Cash and equivalents - - - - -
Total current liabilities 16.34M 18.35M 29.50M 21.18M 3.68M
Current deferred revenue - - - - -
Net debt 4.58M -7.49400M -128.96500M -135.00200M -158.87400M
Short term debt 3.37M 3.27M - - -
Short long term debt - - - - -
Short long term debt total 26.29M 27.11M - - -
Other stockholder equity 705.79M 694.73M 675.35M 147.61M 233.01M
Property plant equipment - 22.52M 23.81M 2.79M 1.09M
Total current assets 117.96M 197.04M 325.07M 317.18M 165.78M
Long term investments - - - - -
Net tangible assets - 201.37M 318.66M 304.71M -56.25300M
Short term investments 92.58M 155.01M 186.81M 169.81M -
Net receivables - 4.27M 6.20M 8.03M -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.30M 4.07M 9.45M 5.26M 0.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.04300M -0.96600M -0.41300M -0.01200M -0.13400M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00500M 0.00400M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -492.40600M -356.28100M -170.90000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.43M 4.27M 6.20M 5.23M 11.75M
Deferred long term asset charges - - - - -
Non current assets total 32.59M 46.51M 30.01M 8.03M 12.84M
Capital lease obligations 26.29M 27.11M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 30.47M -20.17200M -170.46000M -170.46000M -2.54300M
Change to liabilities -12.75000M 6.18M 16.79M 0.40M 0.21M
Total cashflows from investing activities 25.20M -45.81400M -172.10600M -1.69300M -2.54300M
Net borrowings - - - - -
Total cash from financing activities -1.35300M 166.66M 228.75M 175.60M 45.97M
Change to operating activities -3.07900M 9.22M 9.85M -6.34100M -8.73600M
Net income -136.12500M -185.38600M -112.23200M -45.63400M -12.77000M
Change in cash -94.36400M -6.03700M -23.87200M 134.01M 24.86M
Begin period cash flow 128.97M 135.00M 158.87M 24.86M 0.00000M
End period cash flow 34.60M 128.97M 135.00M 158.87M 24.86M
Total cash from operating activities -118.21000M -126.87900M -80.52000M -39.89600M -18.56700M
Issuance of capital stock 0.00000M 165.81M 228.26M 176.19M 45.97M
Depreciation 3.68M 1.54M 0.80M 0.13M 0.13M
Other cashflows from investing activities -3.00000M -8.00000M -0.50000M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.40M 0.21M
Sale purchase of stock 0.30M 0.89M 0.28M - -
Other cashflows from financing activities -1.78600M -0.03700M 0.21M 175.60M 45.97M
Change to netincome 18.95M 32.69M 14.58M 11.55M 2.73M
Capital expenditures 5.27M 25.64M 1.65M 1.69M 2.54M
Change receivables - - - - -
Cash flows other operating 7.26M 15.31M -1.08600M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -94.36400M -6.03700M -23.87200M - -
Change in working capital -8.49100M 11.42M 14.44M -5.94300M -8.52400M
Stock based compensation 18.95M 32.69M 14.58M 1.45M -
Other non cash items 3.77M 10.07M 1.26M 0.95M 2.73M
Free cash flow -123.48400M -152.52100M -82.16600M -41.58900M -21.11000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PASG
Passage Bio Inc		 -0.24 3.92% 5.88 - - - 0.75 0.05
NVO
Novo Nordisk A/S		 -0.01 0.02% 47.41 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 6.78 1.45% 475.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.40 0.87% 623.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio Inc

One Commerce Square, Philadelphia, PA, United States, 19103

Key Executives

Name Title Year Born
Dr. William Chou M.D. CEO & Director NA
Dr. James M. Wilson M.D., Ph.D. Co-Founder & Chief Scientific Advisor 1955
Ms. Simona King CFO & Corp. Sec. 1972
Mr. Alexandros Fotopoulos MBA, MSc Chief Technical Officer 1969
Mr. Stuart M. Henderson VP of Corp. Devel. & Investor Relations NA
Mr. Edgar B. Cale Esq., J.D. Gen. Counsel & Company Sec. 1964
Gregory Fuest VP of Global Commercial Strategy & Marketing NA
Dr. Mark Forman M.D., Ph.D. Chief Medical Officer 1964
Desiree Luthman D.D.S. Sr. VP of Global Regulatory Affairs NA
David Weinstein M.D. Sr. VP of Clinical Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.